CLNN Clene Inc.

NASDAQ
$4.14

Clene Inc. (CLNN) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.43 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.5% since its last earnings release on August 14, 2026.

Clene Missed Consensus Estimates
Friday, August 14, 2026 · 8:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 13
Friday · 8:00 AM ET
Earnings Whisper
-
vs ($0.43)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.85

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Clene Inc.

Clene, a clinical-stage biopharmaceutical company focused on neurodegenerative disease, is leading the way by using nanotechnology to treat bioenergetic failure, which underlies many neurological diseases.

Sector

Healthcare

Industry

Biotechnology